In 2019, He et al[38] demonstrated that the expression levels of P-gp were correlated with cisplatin efficacy in osteosarcoma patients; sh-RNA-based molecular knockdown of P-gp led to sensitization of osteosarcoma cells to cisplatin; furthermore, knocking down of P-gp in osteosarcoma was shown to be a potential approach for overcoming cisplatin resistance; and the extensive role of drug efflux mechanisms and their components in cancer drug resistance make them potential targets for therapeutic interventions. Here, PGP is linked to cancer.